Who are paricalcitol capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): paricalcitol capsule, Paricalcitol: Zemplar®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paricalcitol-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

paricalcitol capsules — Competitive Intelligence Brief

paricalcitol capsules (paricalcitol capsules) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D receptor agonist. Area: Nephrology / Endocrinology.

marketed Vitamin D receptor agonist Vitamin D receptor (VDR) Nephrology / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

paricalcitol capsules (paricalcitol capsules) — Abbott. Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphate metabolism and suppress parathyroid hormone secretion.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
paricalcitol capsules TARGET	paricalcitol capsules	Abbott	marketed	Vitamin D receptor agonist	Vitamin D receptor (VDR)
paricalcitol capsule	paricalcitol capsule	Abbott	marketed	Vitamin D receptor agonist	Vitamin D receptor (VDR)
Paricalcitol: Zemplar®	Paricalcitol: Zemplar®	Hospital Universitario de Canarias	marketed	Vitamin D receptor agonist	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin D receptor agonist class)

Abbott · 2 drugs in this class
Hospital Universitario de Canarias · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). paricalcitol capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/paricalcitol-capsules. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab